Brief: TG Therapeutics Reports Q3 Results And Raises Briumvi® Annual Revenue Guidance
04/11/2024 15:35
Nov 4 (Reuters) - TG Therapeutics Inc TGTX.O :
* TG THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL
RESULTS AND
RAISES BRIUMVI® (UBLITUXIMAB-XIIY) FULL YEAR REVENUE GUIDANCE
* TG THERAPEUTICS INC: RAISES FULL YEAR 2024 U.S. BRIUMVI
NET
REVENUE TARGET TO $300 - $305 MILLION
Source text: ID:nGNX3r9GKg
Further company coverage: TGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TG Therapeutics
See all newsTG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj